Exagen Inc. (XGN)
NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 1.4000 |
| Open | 1.4100 |
| Bid | 1.3800 x 100 |
| Ask | 0.0000 x 0 |
| Day's range | 1.3850 - 1.4128 |
| 52-week range | 1.3000 - 3.9230 |
| Volume | |
| Avg. volume | 37,942 |
| Market cap | 24.339M |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3400 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.50 |
GlobeNewswireExagen Inc. Announces Changes to the Board of Directors
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the
Simply Wall St.Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report
A week ago, Exagen Inc. ( NASDAQ:XGN ) came out with a strong set of annual numbers that could potentially lead to a...
Simply Wall St.Exagen Full Year 2023 Earnings: Beats Expectations
Exagen ( NASDAQ:XGN ) Full Year 2023 Results Key Financial Results Revenue: US$52.5m (up 15% from FY 2022). Net loss...
© 2024 Yahoo. All rights reserved.